European Psychiatry - Volume 41 - April 2017

202 / 916

S198 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237
EW0271
Effect of two long-acting treatments,
the paliperidone palmitate 1-month
and 3-month formulations on
caregiver burden in European patients
with schizophrenia
L. Hargarter ∗, S. Gopal , H. Xu , K. McQuarrie , A. Savitz ,
I. Nuamah , K. Woodruff , M. Mathews
1 Janssen-Cilag GmbH, Janssen-Cilag GmbH, Neuss, Germany
2 Janssen Research & Development, Central nervous system,
Titusville, USA
3 Janssen Research & Development, Clinical Biostats, Titusville, USA
4 Janssen Research & Development, Hub General, Titusville, USA
5 Janssen Research & Development, HECOR, Horsham, USA
6 Janssen Research & Development, FRANCHISE AND NBD, Titusville,
USA
∗ Corresponding author.
Introduction Schizophrenia puts a significant burden on care-
givers.
Objectives To explore the effects of two long-acting treatments
(LAT), paliperidone palmitate 1-month and 3-month formulations
on caregiver burden (CGB) in European patients with schizophrenia
using the Involvement Evaluation Questionnaire (IEQ)
Aims To conduct a subgroup analysis of two randomized, double-
blind studies (NCT01515423 and NCT01529515).
Methods Caregivers (≥ 1 h of contact/week with the patients)
were offered to complete the IEQ (31 items, each scoring: 0–4; total
score: sum of 27 items [0–108]).
Results Among 756 European caregivers (53% parents, 18%
spouse/partner or girl/boyfriend, 10% sister/brother), 60% reported
a CGB of ≥ 32 hours/week at open-label baseline (BL-OL). CGB
reduced significantly for patients with both BL-OL and at least one
double-blind IEQ sum-score (n = 433):mean improvement [SD] (9.9
[12.66], P < 0.001) from BL-OL (mean [SD] 26.0 [13.30]) to study
end (16.0 [10.47]); (reduction in burden associated with worrying
[2.9 points] and urging [4.3 points]). CGB significantly improved
in patients on prior oral antipsychotics post-switching to LAT
with less leisure days impacted and less hours spent in caregiving
(P < 0.001). There was significant relationship between improve-
ments and relapse status, patient age ( P < 0.001), age at diagnosis
(P < 0.002), and number of prior psychiatric hospitalizations in the
last 24months (P < 0.05). Prior use of long-acting antipsychotics
other than paliperidone palmitate 1-month or 3-month formula-
tions at BL-OL and duration of prior psychiatric hospitalizations in
the last 24months didnot showsignificant effect on improvements.
Conclusion Switching from an oral antipsychotic to an LAT can
provide a meaningful and significant improvement in caregiver
burden.
Disclosure of interest All authors are employees of Janssen
Research & Development, LLC and hold stocks in the company.
EW0272
Comorbidities in patients with an
at-risk mental state and first episode
psychosis
U. Heitz ∗, J. Cherbuin , S. Menghini-Müller , L. Egloff , S. Ittig ,
K. Beck , C. Andreou , E. Studerus , A. Riecher-Rössler
University of Basel Psychiatric Hospital, Center for gender research
and early detection, Basel, Switzerland
∗ Corresponding author.
Introduction Non-psychotic axis I diagnoses are highly prevalent
in at-risk mental state (ARMS) and first episode psychosis (FEP)
patients, the most common being affective and anxiety disorders.
Few studies have examined differences between ARMS and FEP
patients or gender effects regarding such diagnoses.
Objective To examine current and lifetime comorbidities inARMS
and FEP patients. Furthermore, to examine gender differences, and
differences between patients with (ARMS-T) and without later
transition to psychosis (ARMS-NT).
Methods This study was part of the Früherkennung von Psycho-
sen (FePsy) study. Current and lifetime axis I comorbidities were
assessed using the Structured Clinical Interview for DSM-IV (SCID-
I).
Results One hundred and thirty-two ARMS and 98 FEP patients
were included. Current comorbidities were present in 53.1% of FEP
and 64.4% of ARMS patients, themost common being affective, anx-
iety and substance use disorders. Current affective disorders were
significantly more common in ARMS than FEP. Lifetime comorbidi-
ties were diagnosed in 58.2% of FEP and 69.7% of ARMS patients,
with significantly more affective and anxiety disorders in ARMS
than FEP. Male FEP patients had more current and lifetime sub-
stance use disorders (across all substances) compared to female
FEP. No differences emerged between ARMS-T and ARMS-NT.
Conclusions As expected ARMS patients have many comorbidi-
ties, while clearly diagnosed FEP have less comorbidities. There
were few gender differences in axis I comorbidities. Moreover,
no differences between ARMS-T and NT emerged, suggesting that
axis I comorbidities do not improve prediction of transition. Nev-
ertheless, the high comorbidity prevalence is relevant for global
functioning and clinical treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0273
Visual and motor functions in
schizophrenia
A. Hopulele-Petri ∗ Manea
1 County Emergency Hospital, Psychiatry, Cluj-Napoca, Romania
2 University Of Medicine And Pharmacy “Carol Davila”, Psychiatry,
Bucharest, Romania
∗ Corresponding author.
Introduction Over the past decade, perceptual organization has
gained an increasingly important role in the psychopathology
of schizophrenia. With the advancements in visual neurocogni-
tive sciences, visual processing, especially mid- and high-level
processing have been linked with psychotic symptoms, as well as
prodromal and ultra-high risk patients. Motor dysfunction is being
seen as well as an integral element of schizophrenia, separate from
the other symptoms and with possible implications for disease risk
and outcome. This could illustrate two systems at work, which by
either individual dysfunction or integrative disorganization help
explain some the neurocognitive mechanisms in schizophrenia.
Objective and aims The current study’s argument is that tests
from these two domains could be used in a complementary man-
ner to offer a neurocognitive characterization of schizophrenic
patients.
Methods A total of 24 patients and 19 controls were evalu-
ated. In order to assess mid-level visual perception the Leuven
Perceptual Organization Screening Test was used, along with a
scale for assessing soft neurological signs and a task for gait and
motor imagery. Clinical symptoms were measured with the Posi-
tive And Negative Symptoms Scale, using the five-factor model as
proposed by Lindenmayer. Data analysis involved comparison of
means between patient and control groups as well as a multivari-
ate factor analysis calculating the impact of perceptual and motor
functions on clinical symptoms.
Results Consistent with previous findings, visual andmotor func-
tions would differentiate between patient and control groups. In